FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 551 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Patient Guide in Testicular Cancer Now Available Also in Italian November 25, 2025 Cancer in My Community: Addressing Health Disparities in Brazil July 18, 2023 ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 Cancer in My Community: Obstacles to Caring for People With Cancer... November 23, 2020 Load more HOT NEWS After Being Told a Lump Was Benign, Teenager Learns She Has... Liquid Biopsies on the Horizon for Children with Solid Cancers Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated... How to Find the Right Hospice Care Program for You or...
